Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | LTK | P29376 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16828091 | 0.80 | PDE10A (0.43) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL1018372 | 0.80 | PDE10A (0.67) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL14316241 | 0.80 | CDK2 (0.46) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL4431791 | 0.80 | ALDH1A1 (0.50) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL30974 | 0.80 | PDE10A (0.67) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL7846977 | 0.76 | PRKAB2 (0.48) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL7846641 | 0.76 | CHEK1 (0.68) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL31465366 | 0.76 | CDK2 (0.43) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL17787543 | 0.76 | CHEK1 (0.43) | CDK2CHEK1CCNA2CCNA1PDE10A | |
| SCHEMBL14670969 | 0.76 | PDE10A (0.40) | CDK2CHEK1CCNA2CCNA1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717312-A1 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES USEFUL AS A MEDICAMENT | Perha Pharmaceuticals (FR) | 2026-04-01 | — | — | EP | disclosed |
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | Carrick Therapeutics Limited (IE) | 2025-11-18 | — | — | US | disclosed |
| CN-114929708-B | 4- [ [ (7-Aminopyrazolo [1,5-a ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic uses | 卡里克治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117940427-A | Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof | 卡里克治疗有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2023-05-11 | — | — | US | disclosed |
| US-9932344-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932344-B2 | Pyrazolo[1,5-A]pyrimidine-5,7-diamine compounds as CDK inhibitors and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-04-03 | — | — | US | disclosed |
| EP-3107914-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-28 | — | — | EP | disclosed |
| EP-3107914-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | IP2IPO INNOVATIONS LIMITED (GB) | 2016-12-15 | — | — | US | disclosed |
| WO-2015124941-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015124941-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362410-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK10, CDK1, CDK20 | CDK2 7/4885CHEK1 130/4885CCNA2 32/4885 |
| US-20230144197-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | CDK1, CDK3, CDK2 | CDK2 3/4885CHEK1 24/4885CCNA2 40/4885 |
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | CDK3, CDK1, CDK2 | CDK2 3/4885CHEK1 27/4885CCNA2 33/4885 |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | CDK10, CDK1, CDK20 | CDK2 6/4885CHEK1 93/4885CCNA2 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.